These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 37992872)
1. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872 [TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026 [TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408 [TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832 [TBL] [Abstract][Full Text] [Related]
6. Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study. Slater S; Bryant A; Aresu M; Begum R; Chen HC; Peckitt C; Lazaro-Alcausi R; Carter P; Anandappa G; Khakoo S; Melcher L; Potter V; Marti FM; Huang J; Branagan G; George N; Abulafi M; Duff S; Raja A; Gupta A; West N; Bucheit L; Rich T; Chau I; Cunningham D; Starling N; Clin Cancer Res; 2024 Aug; 30(16):3459-3469. PubMed ID: 38864835 [TBL] [Abstract][Full Text] [Related]
7. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer. Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407 [TBL] [Abstract][Full Text] [Related]
8. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
9. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155 [TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972 [TBL] [Abstract][Full Text] [Related]
12. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694 [TBL] [Abstract][Full Text] [Related]
14. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194 [TBL] [Abstract][Full Text] [Related]
15. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer. Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891 [TBL] [Abstract][Full Text] [Related]
17. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413 [TBL] [Abstract][Full Text] [Related]
18. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783 [TBL] [Abstract][Full Text] [Related]
19. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]